MCID: SCN007
MIFTS: 55

Secondary Hyperparathyroidism

Categories: Bone diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Secondary Hyperparathyroidism

MalaCards integrated aliases for Secondary Hyperparathyroidism:

Name: Secondary Hyperparathyroidism 12 38 15 17
Hyperparathyroidism, Secondary 45
Hyperparathyroidism Secondary 56

Classifications:



External Ids:

Disease Ontology 12 DOID:12466
KEGG 38 H01669
MeSH 45 D006962
NCIt 51 C113335
SNOMED-CT 69 91478007
ICD10 34 E21.1
UMLS 74 C0020503

Summaries for Secondary Hyperparathyroidism

MalaCards based summary : Secondary Hyperparathyroidism, also known as hyperparathyroidism, secondary, is related to vitamin d-dependent rickets, type 2a and secondary hyperparathyroidism of renal origin. An important gene associated with Secondary Hyperparathyroidism is CASR (Calcium Sensing Receptor), and among its related pathways/superpathways are Ca, cAMP and Lipid Signaling and Parathyroid hormone synthesis, secretion and action. The drugs Cinacalcet and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and thyroid, and related phenotypes are cellular and growth/size/body region

Wikipedia : 77 Secondary hyperparathyroidism is the medical condition of excessive secretion of parathyroid hormone... more...

Related Diseases for Secondary Hyperparathyroidism

Diseases in the Hyperparathyroidism family:

Hyperparathyroidism 1 Hyperparathyroidism 3
Hyperparathyroidism 4 Primary Hyperparathyroidism
Secondary Hyperparathyroidism

Diseases related to Secondary Hyperparathyroidism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 vitamin d-dependent rickets, type 2a 32.1 CYP27B1 VDR
2 secondary hyperparathyroidism of renal origin 31.5 ACP5 ALB BGLAP CALCA CASR CYP27B1
3 primary hyperparathyroidism 30.9 ALB ALPP BGLAP CALCA CASR FGF23
4 end stage renal failure 30.7 ALB EPO PTH
5 hyperparathyroidism 30.3 ACP5 BGLAP CALCA CASR CYP27B1 EPO
6 calcinosis 30.3 CALCA FGF23 KL
7 hyperparathyroidism, neonatal severe 30.3 CASR NR1I3
8 rickets 30.3 BGLAP CYP27B1 FGF23 PTH VDR
9 osteomalacia 30.2 BGLAP CALCA CASR FGF23 PTH VDR
10 hypocalciuric hypercalcemia, familial, type i 30.2 CASR PTH
11 bone inflammation disease 30.1 ACP5 BGLAP TNFRSF11B
12 idiopathic hypercalciuria 30.0 BGLAP CASR NR1I3 VDR
13 hypophosphatemic rickets, x-linked recessive 30.0 CYP27B1 FGF23 VDR
14 oncogenic osteomalacia 30.0 FGF23 PTH
15 hyperphosphatemia 30.0 CASR FGF23 KL PTH VDR
16 hypophosphatemia 29.9 BGLAP FGF23 PTH
17 calciphylaxis 29.9 ALB CASR EPO FGF23 PTH VDR
18 renal osteodystrophy 29.9 BGLAP CALCA CASR FGF23 PTH TNFRSF11B
19 multiple endocrine neoplasia, type i 29.9 CASR MEN1 PTH
20 parathyroid carcinoma 29.8 CALCA CASR MEN1 PTH
21 nephrolithiasis 29.8 CASR FGF23 PTH VDR
22 familial hypocalciuric hypercalcemia 29.8 CASR PTH SPG7
23 hyperostosis 29.7 FGF23 KL TNFRSF11B
24 kidney disease 29.7 ALB B2M CASR EPO FGF23 PTH
25 parathyroid adenoma 29.6 BGLAP CALCA CASR MEN1 PTH VDR
26 osteitis fibrosa 29.6 B2M BGLAP CALCA CASR PTH
27 bone resorption disease 29.5 ACP5 BGLAP CALCA PTH TNFRSF11B VDR
28 uremia 29.4 ALB B2M CASR EPO PTH TNFRSF11B
29 osteonecrosis 29.4 ACP5 BGLAP PTH TNFRSF11B
30 hypoparathyroidism 29.3 ALPP BGLAP CASR FGF23 PTH SPG7
31 myeloma, multiple 29.0 ALB B2M EPO TNFRSF11B
32 chronic kidney failure 28.8 ALB B2M BGLAP CALCA CASR CYP27B1
33 bone disease 28.3 ACP5 ALPP B2M BGLAP CALCA CASR
34 osteoporosis 28.3 ACP5 ALPP BGLAP CALCA CASR CYP27B1
35 non-renal secondary hyperparathyroidism 12.3
36 vitamin d hydroxylation-deficient rickets, type 1a 11.5
37 osteopetrosis, autosomal recessive 1 11.1
38 axial osteomalacia 10.4 BGLAP PTH
39 extraskeletal chondroma 10.4 BGLAP PTH
40 hypocalciuric hypercalcemia, familial, type iii 10.4 CASR PTH
41 hypocalciuric hypercalcemia, familial, type ii 10.4 CASR PTH
42 hypoparathyroidism, familial isolated 10.4 CASR PTH
43 hypercalciuria, absorptive, 2 10.4 CASR VDR
44 parathyroid transitional clear cell adenoma 10.4 MEN1 PTH
45 clear cell adenoma 10.3 MEN1 PTH
46 hepatic tuberculosis 10.3 ALB ALPP
47 tracheal calcification 10.3 FGF23 KL
48 hyperparathyroidism 2 with jaw tumors 10.3 CASR MEN1
49 paget disease of bone 5, juvenile-onset 10.3 CALCA TNFRSF11B
50 impaired renal function disease 10.3 BGLAP FGF23 PTH

Graphical network of the top 20 diseases related to Secondary Hyperparathyroidism:



Diseases related to Secondary Hyperparathyroidism

Symptoms & Phenotypes for Secondary Hyperparathyroidism

MGI Mouse Phenotypes related to Secondary Hyperparathyroidism:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 ALB B2M CASR CYP27B1 EPO KL
2 growth/size/body region MP:0005378 10.2 B2M CASR CYP27B1 FGF23 KL MEN1
3 cardiovascular system MP:0005385 10.14 B2M EPO FGF23 KL MEN1 PTH
4 homeostasis/metabolism MP:0005376 10.14 ALB B2M CASR CYP27B1 EPO FGF23
5 endocrine/exocrine gland MP:0005379 10.13 ALB B2M CASR CYP27B1 FGF23 KL
6 hematopoietic system MP:0005397 10.09 B2M CASR CYP27B1 EPO FGF23 KL
7 immune system MP:0005387 10.07 B2M CASR CYP27B1 EPO FGF23 KL
8 digestive/alimentary MP:0005381 10.04 ALB B2M CASR FGF23 KL MEN1
9 craniofacial MP:0005382 9.99 CYP27B1 KL MEN1 PTH TNFRSF11B VDR
10 mortality/aging MP:0010768 9.9 ALB B2M CASR EPO FGF23 KL
11 integument MP:0010771 9.87 B2M CASR CYP27B1 EPO FGF23 KL
12 limbs/digits/tail MP:0005371 9.8 CYP27B1 EPO FGF23 KL PTH TNFRSF11B
13 muscle MP:0005369 9.43 ALB CASR EPO KL MEN1 VDR
14 skeleton MP:0005390 9.28 CASR CYP27B1 EPO FGF23 KL PTH

Drugs & Therapeutics for Secondary Hyperparathyroidism

Drugs for Secondary Hyperparathyroidism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cinacalcet Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 226256-56-0 156419
2
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
4
Sevelamer Approved Phase 4,Phase 3,Phase 2,Not Applicable 52757-95-6
5
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9002-64-6
6
Calcium acetate Approved, Investigational Phase 4,Phase 3,Not Applicable 62-54-4
7
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
8
Ethanol Approved Phase 4 64-17-5 702
9
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
10
Racepinephrine Approved Phase 4 329-65-7 838
11
Angiotensin II Approved, Investigational Phase 4,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
12
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
13
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 471-34-1
14
Alendronate Approved Phase 4,Phase 2,Not Applicable 66376-36-1, 121268-17-5 2088
15
Atorvastatin Approved Phase 4 134523-00-5 60823
16
Zoledronic Acid Approved Phase 4,Phase 1 118072-93-8 68740
17
Pamidronate Approved Phase 4 40391-99-9 4674
18
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
19
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
20
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1406-16-2
21
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-70-2 271
22
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
23
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 67-97-0 5280795 6221
24
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 32222-06-3 5280453 134070
25
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
26
Calcifediol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 19356-17-3 5283731 6433735
27
Alfacalcidol Approved, Nutraceutical Phase 4,Not Applicable 41294-56-8 5282181
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
29
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
30 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Ergocalciferols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Calcimimetic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Vitamin D2 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Calciferol Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 1 alpha-hydroxyergocalciferol Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 retinol Phase 4
47 Retinol palmitate Phase 4
48 Hydroxycholecalciferols Phase 4,Phase 3,Phase 2,Not Applicable
49 Hematinics Phase 4
50 Epoetin alfa Phase 4 113427-24-0

Interventional clinical trials:

(show top 50) (show all 237)
# Name Status NCT ID Phase Drugs
1 Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
2 Intravenous Paricalcitol in Chronic Hemodialysis Patients Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
3 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4 Vitamin D2
4 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
5 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
6 Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition Unknown status NCT02005302 Phase 4 1,25(OH)2 Vitamin D3;Vitamin D2
7 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
8 Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
9 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
10 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
11 Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
12 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
13 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
14 START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
15 Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
16 Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
17 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
18 20070360 Incident Dialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
19 Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level Completed NCT01101113 Phase 4 cinacalcet;control
20 A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
21 Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
22 A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
23 Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
24 Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
25 Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
26 Treatment Adhesion in Dialysis Patients Treated With Cinacalcet Completed NCT01573520 Phase 4
27 A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) Completed NCT00431496 Phase 4 Cinacalcet
28 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
29 A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
30 Trial to Optimize Mineral Outcomes in Dialysis Patients Completed NCT01100723 Phase 4
31 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Completed NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
32 Vitamin D and Coronary Calcification Study Completed NCT00752102 Phase 4 Calcitriol (Rocaltrol®);Paricalcitol
33 A Research Study for Patients With End-Stage Renal Disease (ESRD) Completed NCT00110890 Phase 4 cinacalcet
34 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
35 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
36 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
37 Physiologic Interactions Between the Adrenal- and the Parathyroid Glands Completed NCT02572960 Phase 4 Valsartan;Placebo Valsartan
38 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
39 Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol Completed NCT01748396 Phase 4 Calcitriol;Calcium Carbonate
40 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4 Calcitriol
41 Cholecalciferol Supplementation Effect on Parathyroid Hormone in Hemodialysis Patients Completed NCT03648528 Phase 4 cholecalciferol;placebo
42 Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Completed NCT02238418 Phase 4 Cholecalciferol vial (100 000 UI)
43 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4 Vitamin D2;1,25(OH)2 Vit D3
44 Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease Completed NCT00395382 Phase 4 Alendronate;Placebo
45 How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis Completed NCT00528788 Phase 4 doxercalciferol
46 ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
47 A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264) Completed NCT01350934 Phase 4 alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus);Calcitriol
48 The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid Completed NCT02056730 Phase 4 calcium sensing receptor agonist
49 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
50 Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation Completed NCT01675089 Phase 4 Zoledronic acid

Search NIH Clinical Center for Secondary Hyperparathyroidism

Cochrane evidence based reviews: hyperparathyroidism, secondary

Genetic Tests for Secondary Hyperparathyroidism

Anatomical Context for Secondary Hyperparathyroidism

MalaCards organs/tissues related to Secondary Hyperparathyroidism:

42
Kidney, Bone, Thyroid, Heart, Prostate, Endothelial, Spinal Cord

Publications for Secondary Hyperparathyroidism

Articles related to Secondary Hyperparathyroidism:

(show top 50) (show all 1887)
# Title Authors Year
1
The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. ( 31014177 )
2019
2
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. ( 31015494 )
2019
3
Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism. ( 31022778 )
2019
4
Plasma metabolite biomarkers related to secondary hyperparathyroidism and parathyroid hormone. ( 31069832 )
2019
5
A Bayesian network analysis on comparative efficacy of treatment strategies for dialysis patients with secondary hyperparathyroidism. ( 30651833 )
2019
6
Medication Prescription Patterns for Secondary Hyperparathyroidism: More Questions than Answers. ( 30665921 )
2019
7
US-guided microwave ablation for secondary hyperparathyroidism in patients after renal transplantation: a pilot study. ( 30676132 )
2019
8
Peritoneal dialysis can alleviate the clinical course of hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. ( 30689179 )
2019
9
Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients. ( 30699421 )
2019
10
Effects of Long-Term Cinacalcet Administration on Parathyroid Gland in Hemodialysis Patients with Secondary Hyperparathyroidism. ( 30712039 )
2019
11
Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism. ( 30738215 )
2019
12
Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet. ( 30756425 )
2019
13
Subtotal Parathyroidectomy vs Total Parathyroidectomy with Autotransplantation for Secondary Hyperparathyroidism in Dialysis Patients: Short- and Long-Term Outcomes. ( 30776511 )
2019
14
Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. ( 30794689 )
2019
15
Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study-A Comparison. ( 30804890 )
2019
16
Microwave ablation vs. parathyroidectomy for secondary hyperparathyroidism in maintenance hemodialysis patients. ( 30815995 )
2019
17
Simultaneous spontaneous bilateral quadriceps tendon rupture with secondary hyperparathyroidism in a patient receiving hemodialysis: A case report. ( 30855501 )
2019
18
One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. ( 30859218 )
2019
19
An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. ( 30875390 )
2019
20
Aiming Too Low: Reevaluation of Target Concentrations of Serum 25-Hydroxyvitamin D in Secondary Hyperparathyroidism. ( 30879016 )
2019
21
Influence of Pre-renal Transplant Secondary Hyperparathyroidism on Later Evolution After Transplantation. ( 30879538 )
2019
22
Refractory secondary hyperparathyroidism in waiting list for parathyroidectomy: who we should operate first in a quaternary hospital in Brazil regarding survival. ( 30942649 )
2019
23
Intraoperative verification of parathyroid glands in primary and secondary hyperparathyroidism using near-infrared autofluorescence (IOPA). ( 30945149 )
2019
24
Corrigendum to "Effects of parathyroidectomy on the biology of bone tissue in patients with chronic kidney disease and secondary hyperparathyroidism" [Bone 121 (April 2019) 277-283]. ( 30954866 )
2019
25
A practical self-made device in parathyroid autotransplantation for patients with secondary hyperparathyroidism. ( 30198369 )
2019
26
The Importance of Adherence in the Treatment of Secondary Hyperparathyroidism. ( 30223271 )
2019
27
Conservative three-quarter versus subtotal seven-eighths parathyroidectomy in secondary hyperparathyroidism. ( 30327179 )
2019
28
Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies. ( 30328270 )
2019
29
Pharmacology of Parsabiv® (etelcalcetide, ONO-5163/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients. ( 30342948 )
2019
30
Analysis of the role of thyroidectomy and thymectomy in the surgical treatment of secondary hyperparathyroidism. ( 30472135 )
2019
31
Parathyroidectomy decreases serum intact parathyroid hormone and calcium levels and prolongs overall survival in elderly hemodialysis patients with severe secondary hyperparathyroidism. ( 30485538 )
2019
32
Corrigendum to "Quality of life after surgery in secondary hyperparathyroidism comparing subtotal parathyroidectomy to total parathyroidectomy with immediate parathyroid autograft - a prospective randomized trial" [Surgery 164 (2018) 978-985]. ( 30501922 )
2019
33
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. ( 30506144 )
2019
34
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. ( 30159688 )
2019
35
Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism. ( 29492624 )
2018
36
Unusually Large Brown tumor of Mandible in a Case of Secondary Hyperparathyroidism Mimicking Cherubism. ( 29643674 )
2018
37
Periosteal chondroma of the cuboid with secondary aneurysmal bone cyst in a setting of secondary hyperparathyroidism. ( 29413778 )
2018
38
Changes in serum FGF23 and Klotho levels and calcification scores of the abdominal aorta after parathyroidectomy for secondary hyperparathyroidism. ( 30594298 )
2018
39
Secondary hyperparathyroidism among Nigerians with chronic kidney disease. ( 30602972 )
2018
40
Reproductive disorders, osteoporosis and secondary hyperparathyroidism with celiac disease. ( 30701802 )
2018
41
Acute neurological syndrome complicating secondary hyperparathyroidism. ( 30949005 )
2018
42
Association of Vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease. ( 30234059 )
2018
43
Evocalcet in the management of secondary hyperparathyroidism in dialysis patients. ( 30243312 )
2018
44
Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ( 29247451 )
2018
45
Brown tumor of the cervical spine in a patient with secondary hyperparathyroidism: A case report. ( 30245355 )
2018
46
Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. ( 30254496 )
2018
47
Sixty-Two-Year-Old Male Suffering From Uremic Leontiasis Ossea Caused by Severe Secondary Hyperparathyroidism. ( 30283905 )
2018
48
A novel device in parathyroid autotransplantation for 6 patients with secondary hyperparathyroidism - Case series. ( 30294428 )
2018
49
Craniofacial Brown Tumor in Patients with Secondary Hyperparathyroidism to Chronic Renal Failure: Report of Two Cases in Cipto Mangunkusumo Hospital. ( 30298112 )
2018
50
Mediastinal Remnant Thymic Tissue Misdiagnosed as Ectopic Parathyroid Hyperplasia in Secondary Hyperparathyroidism. ( 30325824 )
2018

Variations for Secondary Hyperparathyroidism

Expression for Secondary Hyperparathyroidism

Search GEO for disease gene expression data for Secondary Hyperparathyroidism.

Pathways for Secondary Hyperparathyroidism

GO Terms for Secondary Hyperparathyroidism

Cellular components related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 ALB B2M BGLAP CALCA EPO FGF23
2 endoplasmic reticulum lumen GO:0005788 9.35 ALB B2M BGLAP FGF23 MEN1
3 extracellular space GO:0005615 9.28 ALB B2M BGLAP CALCA EPO FGF23

Biological processes related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.92 B2M BGLAP PTH TNFRSF11B
2 regulation of signaling receptor activity GO:0010469 9.85 CALCA EPO FGF23 KL PTH TNFRSF11B
3 skeletal system development GO:0001501 9.83 BGLAP PTH TNFRSF11B VDR
4 ossification GO:0001503 9.76 ACP5 BGLAP CASR
5 aging GO:0007568 9.73 BGLAP EPO KL
6 cellular protein metabolic process GO:0044267 9.72 ALB B2M CALCA FGF23 MEN1
7 cellular calcium ion homeostasis GO:0006874 9.65 CASR PTH VDR
8 calcium ion transport GO:0006816 9.64 CYP27B1 VDR
9 bone resorption GO:0045453 9.63 ACP5 PTH
10 decidualization GO:0046697 9.63 CYP27B1 MEN1 VDR
11 osteoblast development GO:0002076 9.62 BGLAP MEN1
12 positive regulation of keratinocyte differentiation GO:0045618 9.61 CYP27B1 VDR
13 negative regulation of bone resorption GO:0045779 9.61 CALCA TNFRSF11B
14 regulation of bone mineralization GO:0030500 9.61 BGLAP CYP27B1 FGF23
15 response to inorganic substance GO:0010035 9.6 BGLAP TNFRSF11B
16 response to magnesium ion GO:0032026 9.59 FGF23 TNFRSF11B
17 phosphate ion homeostasis GO:0055062 9.58 FGF23 PTH
18 response to vitamin D GO:0033280 9.58 BGLAP CYP27B1 PTH
19 response to fibroblast growth factor GO:0071774 9.57 CASR PTH
20 response to estrogen GO:0043627 9.56 BGLAP CYP27B1 EPO TNFRSF11B
21 negative regulation of calcium ion transport into cytosol GO:0010523 9.55 CALCA EPO
22 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.54 FGF23 KL
23 bone mineralization GO:0030282 9.51 BGLAP CYP27B1
24 vitamin D catabolic process GO:0042369 9.49 CYP27B1 FGF23
25 vasodilation GO:0042311 9.33 CASR
26 vitamin D metabolic process GO:0042359 9.33 CYP27B1 FGF23 VDR
27 cellular response to vitamin D GO:0071305 9.13 BGLAP CASR FGF23
28 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 8.8 CYP27B1 FGF23 VDR

Molecular functions related to Secondary Hyperparathyroidism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vitamin D binding GO:0005499 8.96 KL VDR
2 hormone activity GO:0005179 8.92 CALCA EPO KL PTH

Sources for Secondary Hyperparathyroidism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....